Although Abbott has recently gained on positive trial results, Gilead Sciences remains in the forefront of the market.
Both companies want to develop a replacement to the standard year-long injection treatment.
The company's Abraxane delays tumor growth in patients with advanced melanoma.
The drug company is a defensive, income generator with added potential for capital gains.
Bristol-Myers Squibb is upgraded to 'conviction buy' at Goldman, and Yelp is initiated with a 'neutral' at Piper Jaffray.
Despite the current gloom, the market is in a heck of a better place than it was 12 months ago.
The US approval of Stribild is a big plus for the company's AIDS treatment franchise.
VIDEO ON MSN MONEY
Copyright © 2014 Microsoft. All rights reserved.
The S&P 500 manages to keep a deathgrip on 2,000, but key areas of the market are already buckling under pressure.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
Six weeks later, most Americans have forgotten about the 2014 tax season -- except those who didn't file by the April 15 deadline.
MUST-SEE ON MSN
A charcuterie master shares his process for cold-smoking meat at home.
- Jetpacks about to go mainstream
- Weird things covered by home insurance
- Bing: 70 percent of adults report 'digital eye strain'